What Eagle Genomics does

Eagle Genomics is a UK-based TechBio company founded in 2008 that developed e[datascientist], an AI-augmented platform applying network science to microbiome data analysis. The platform addressed 'One Health' challenges spanning human, animal, and environmental health by enabling researchers and organizations to analyze complex microbial ecosystems, accelerate product development, and support evidence-based innovation across the discovery, development, and clinical validation lifecycle. The company targeted enterprise customers in four primary verticals: BioPharma (drug discovery and development), Food and Nutrition (product formulation and gut health), Beauty (skin microbiome research and cosmetic formulation), and AgBio (soil and plant microbiome analysis), with secondary applications in Healthcare and Consumer Products. Business model was enterprise B2B platform licensing/subscription with direct field sales targeting large organizations globally.

The company raised over £20 million in disclosed funding across multiple rounds dating back to 2013, with the largest being a USD 20 million scale-up round in October 2022 led by abrdn plc, followed by a £3 million round in September 2023 led by Granpool Innovative Investments. In September 2023, Dr Victoria Kimonides was appointed CEO and John Schoellerman as Chair. In January 2025, the company divested its core e[datascientist] platform to Cmbio via asset acquisition, and the company website is currently parked. Eagle Genomics remains technically operating but with its primary technology asset transferred to a third party.

Name

Eagle Genomics

Legal name

Eagle Genomics

Website

https://eaglegenomics.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Eagle Genomics is a UK-based TechBio company that built e[datascientist], an AI-augmented network science platform for microbiome data analysis, serving enterprise customers in BioPharma, Food and Nutrition, Beauty, and AgBio. Its core platform was divested to Cmbio in January 2025.

Ownership category

akta.pro rank

Product category

Bioinformatics Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI)

akta.pro secondary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

Keywords

• Microbiome data analytics
• AI-augmented bioinformatics
• Network science platform
• Life sciences data management
• Techbio enterprise software

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Platform Licensing/Subscription: The company operates a TechBio platform business model, generating revenue through licensing its e[datascientist] platform to enterprise customers in pharma, nutrition, beauty, and agriculture sectors

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Eagle Genomics developed and licensed the e[datascientist] platform, an AI-augmented microbiome science platform that applies network science to analyze complex microbial ecosystems. The platform enabled enterprise customers in BioPharma, Food and Nutrition, Beauty, and AgBio to perform microbiome research, AI-powered data analysis, and clinical validation across One Health challenges involving human, animal, and environmental health.

Product overview

Eagle Genomics operated as a TechBio platform offering a single unified product: the e[datascientist] platform. This AI-augmented platform applies network science to microbiome science, enabling data-driven discovery and innovation across industries including Food and Nutrition, Beauty, AgBio, BioPharma, healthcare, agriculture, and consumer products. The platform supported the entire innovation lifecycle from discovery through development and clinical validation. In January 2025, the e[datascientist] platform was acquired by Cmbio.

Differentiator

Problem solved

Functional benefit

Brands

• e[datascientist]: AI-augmented microbiome science platform developed by Eagle Genomics for discovery, development, and clinical validation in the microbiome field

Products and services

• e[datascientist]

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• CmbiomajorOEM/ Whitelabel/ Licensing Partner · 27 January 2025Cmbio acquired Eagle Genomics' e[datascientist] platform in January 2025. This represents a significant licensing/asset acquisition where Cmbio obtained the platform technology to integrate into their Digital Biology offering combining multi-omics, AI, and systems biology capabilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• DNAnexus: DNAnexus provides a cloud-based bioinformatics and genomics data platform for life sciences R&D. Eagle Genomics' e[datascientist] platform played in the same category of AI-augmented scientific data management and analytics platforms serving pharma and life-science customers.
• Benchling: Benchling delivers a cloud-based R&D platform for biotech, with strong adoption across pharma and emerging biotech. It competes for the same enterprise life-sciences data management and workflow budget as Eagle Genomics' platform.
• Genedata: Genedata provides specialized bioinformatics and R&D data management software for pharma, agbio and industrial biotech. It overlaps directly with Eagle Genomics' enterprise software positioning for omics and microbiome analytics workflows.
• Seven Bridges Genomics: Seven Bridges offers a bioinformatics platform for genomics and multi-omics data analysis, with customers in pharma and research. Comparable to Eagle Genomics' microbiome-focused AI-augmented analytics platform, particularly for large-scale life-sciences data.
• Dotmatics: Dotmatics offers a scientific R&D informatics platform spanning biology, chemistry, and formulation workflows. It is a direct enterprise-software peer competing for the same pharma/nutrition/AgBio R&D budgets that Eagle Genomics targeted.
• CosmosID: CosmosID operates a microbial genomics and microbiome analytics platform using AI/ML for identification and characterization of microorganisms. Directly comparable to Eagle Genomics' e[datascientist] platform, which applied AI-augmented network science to microbiome data analysis.

Broad incumbents

• QIAGEN (CLC bio): QIAGEN's CLC bio portfolio offers industry-standard bioinformatics software for genomics, microbiome and multi-omics analysis. As a much larger incumbent with broader reach, it competes in the same analytics and interpretation layer that Eagle Genomics targeted.
• Illumina (microbiome analytics): Illumina provides sequencing platforms and downstream analytics (e.g., 16S/metagenomic workflows) used in microbiome research. While primarily a sequencing incumbent, its analytics stack overlaps with the consumer base of microbiome analytics platforms like Eagle Genomics.

Market position

Strengths3 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/eaglegen

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds13 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eagle Genomics